The year 2025 marked a transformational period for Cypherpunk, following a $58.88 million private placement led by Winklevoss Capital. This funding allowed the company to rebrand itself as a privacy technology firm with a focus on digital asset treasury strategies centered around Zcash. The company has since acquired 294,743.10 ZEC for its treasury and made a strategic investment of $5 million in Zcash Open Development Lab (ZODL), which is the development team behind Zodl, a leading Zcash wallet.
Douglas E. Onsi, President and CEO of Cypherpunk, stated, "Since we began operating as Cypherpunk in October, we have made significant strides in advancing the adoption of Zcash and expanding our efforts across a broad set of technologies that defend privacy."
The company also highlighted its subsidiary Leap Therapeutics, which is advancing the development of sirexatamab for colorectal cancer treatment. The final clinical data from the DeFianCe study presented in October 2025 showed promising results, indicating a statistically significant benefit in overall response rate and progression-free survival for patients treated with sirexatamab compared to the control group.
Overall, Cypherpunk’s strategic investments and operational efficiencies have positioned the company for a strong outlook in 2026, with a commitment to enhancing privacy technologies and expanding its digital asset portfolio.
